causal
Early Development Work Carries Little Profit Upfront
NADS partners with drug developers early in development, customizing oligonucleotides while earning little money, with the payback arriving if the drug reaches commercialization and volume ramps.
causalpending
Speaker
MarcEvidence Quote
“But the payback is if they make it to commercialization and some of them are now moving to commercialization, that the volume really ramps.”
Created: 11/12/2026, 11:55:35 AM
Your notes
Loading notes...